Israel Englander Argenx Se Put Options Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$434.22 - $551.9 $12.8 Million - $16.2 Million	-29,400 Reduced 65.77%	15,300 $8.3 Million
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $7.19 Million - $9.12 Million	20,200 Added 82.45%	44,700 $19.2 Million
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $5.18 Million - $5.99 Million	14,500 Added 145.0%	24,500 $9.65 Million
Q4 2023 Feb 14, 2024	SELL	$338.91 - $506.01 $9.32 Million - $13.9 Million	-27,500 Reduced 73.33%	10,000 $3.8 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $13.5 Million - $15.8 Million	37,500 New	37,500 $14.6 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $3.35 Million - $3.94 Million	9,800 New	9,800 $3.71 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.